Trials / Active Not Recruiting
Active Not RecruitingNCT02750358
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR(+) Triple Negative Breast Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is designed to determine the feasibility of 1 year of adjuvant enzalutamide, an androgen receptor (AR) antagonist for the treatment of patients with early stage, AR(+) triple negative breast cancer (TNBC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enzalutamide | |
| BEHAVIORAL | assessment |
Timeline
- Start date
- 2016-05-19
- Primary completion
- 2026-05-01
- Completion
- 2026-05-01
- First posted
- 2016-04-25
- Last updated
- 2025-06-22
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02750358. Inclusion in this directory is not an endorsement.